Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

33%

Ph early_phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Early Phase 1First-in-human

1(50.0%)

N/ANon-phased studies

1(50.0%)

Highest Phase Reached

Early Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Other(1)

Detailed Status

Recruiting1

Completed1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Early Phase 1

Trials by Phase

Early Phase 11 (50.0%)

N/A1 (50.0%)

Trials by Status

recruiting133%

completed133%

unknown133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingnot_applicable

Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery

NCT05632432

unknown

MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients

NCT04819802

completedearly_phase_1

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

NCT02998775

Clinical Trials (3)

Showing 3 of 3 trials

NCT05632432Not Applicable

Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery

Recruiting

NCT04819802

MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients

Unknown

NCT02998775Early Phase 1

Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3